The Vanguard Group 13D and 13G filings for Haemonetics Corporation:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 5:06 pm Purchase |
2023-12-29 | 13G | Haemonetics Corporation HAE |
The Vanguard Group | 5,406,309 10.650% |
163,473 (+3.12%) |
Filing |
| 2023-02-09 11:22 am Purchase |
2022-12-30 | 13G | Haemonetics Corporation HAE |
The Vanguard Group | 5,242,836 10.360% |
47,641 (+0.92%) |
Filing |
| 2022-10-11 10:07 am Purchase |
2022-09-30 | 13G | Haemonetics Corporation HAE |
The Vanguard Group | 5,195,195 10.120% |
314,259 (+6.44%) |
Filing |
| 2022-02-10 08:16 am Purchase |
2021-12-31 | 13G | Haemonetics Corporation HAE |
The Vanguard Group | 4,880,936 9.550% |
28,654 (+0.59%) |
Filing |
| 2021-02-10 10:57 am Sale |
2020-12-31 | 13G | Haemonetics Corporation HAE |
The Vanguard Group | 4,852,282 9.560% |
-378,913 (-7.24%) |
Filing |